Ad
related to: how bad is cll
Search results
Results from the WOW.Com Content Network
Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [ 2 ] [ 8 ] Early on, there are typically no symptoms. [ 2 ] Later, non-painful lymph node swelling, feeling tired, fever , night sweats , or weight loss for no clear reason may occur.
Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. [1] It is usually classified as a subtype of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up about 2% of all leukemias, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe ...
111,000 (2015) [ 10 ] Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes. [ 1 ] Symptoms may include feeling tired, pale skin color, fever, easy bleeding or bruising, enlarged lymph nodes, or bone pain. [ 1 ]
Leukemia (also spelled leukaemia; pronounced / luːˈkiːmiːə / [1] loo-KEE-mee-ə) is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells. [9] These blood cells are not fully developed and are called blasts or leukemia cells. [2]
Chronic fatigue immune dysfunction syndrome. CFS. Chronic fatigue syndrome. CGBD. Corticobasal ganglionic degeneration. CH. Cluster headache. CHARGE syndrome. Coloboma of the eye, heart defects, atresia of the nasal choanae, retarded growth & or development, genital abnormalities, ear abnormalities.
Richter's transformation (RT), also known as Richter's syndrome, is the conversion of chronic lymphocytic leukemia (CLL) or its variant, small lymphocytic lymphoma (SLL), into a new and more aggressively malignant disease. [1] CLL is the circulation of malignant B lymphocytes with or without the infiltration of these cells into lymphatic or ...
It was approved by the US FDA in April 2016 as a second-line treatment for CLL associated with 17-p deletion. [36] This was the first FDA approval of a BCL-2 inhibitor. [36] In June 2018, the FDA broadened the approval for anyone with CLL or small lymphocytic lymphoma, with or without 17p deletion, still as a second-line treatment. [37]
NK cell leukemia. Aggressive NK-cell leukemia (ANKL) is a lymphoid leukemia that is a deficiency NK cells. Not very much is known about this disease due to its rarity, but it is highly aggressive. A majority of patients with NK cell leukemia die within a year of diagnosis, and for ANKL in particular, half of patients die within two months.
Ad
related to: how bad is cll